Essity

Essity is a global, leading hygiene and health company. Every day, our products, solutions and services are used by a billion people around the world. Our purpose is to break barriers to well-being for the benefit of consumers, patients, caregivers, customers and society. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands such as Actimove, Cutimed, JOBST, Knix, Leukoplast and Libero. In 2024, Essity had net sales of approximately SEK 146bn (EUR 13bn) and employed 36,000 people. The company’s headquarters is located in Stockholm, Sweden and Essity is listed on Nasdaq Stockholm.

Essity’s Purpose ‘Breaking Barriers to Well-being’ creating more value ‘For Everybody and Every Body’. ​​​​​​​

Through our theme Breaking Barriers to Well-being we stimulate and contribute to a global dialogue to increase awareness of the importance of hygiene and health and its link to well-being. Our work aims to raise awareness, improve care and break the silence that surround areas such as menstruation and incontinence. Through collaborations, insight reports, training programs and innovative solutions, we contribute to a more knowledge-based public dialog that drives change and contributes to improving lives for people everywhere.

We may not think about it every day, but what we do is really essential. Every day, our brands care for 1 billion people to live healthier lives and improve their well-being. What we do matters and we have a critical role to play in the world.

Antimicrobial Resistance (AMR) is one of the most urgent challenges facing modern healthcare. An estimated 4.95 million deaths globally were associated with bacterial AMR in 2019, with a projected 8.22 million deaths globally attributed to AMR in 2050. For surgical teams, AMR presents a significant and growing challenge, particularly through the increased risk of Surgical Site Infection (SSI). Because of this, wound dressing selection becomes a critical component of wound care management, infection control and antimicrobial stewardship.
By choosing clinically proven solutions, you can actively contribute to reducing the incidence of SSI and help reduce the burden of AMR across care settings.

Leukomed Sorbact, designed with DACC™ technology, is a promising alternative to antimicrobial dressings and may reduce the need for antibiotics. This Leukomed dressing differs from conventional approaches. Unlike antimicrobial agents that rely on chemical action, Leukomed Sorbact with Sorbact Technology® uses a purely physical mode of action by binding bacteria and fungi to the dressing surface and safely removing them with each dressing change5,6. No active substances are released into the wound, therefore the development of antibiotic resistance is not to be expected.

Best Practice Statement: Antimicrobial Stewardship Strategies for Wound Management Recommendations for the UK has recently been published. This provide an update on guidance and tips to healthcare professions, to support them in aligning to recommended best practice. Get your copy of the latest here: https://medical-images.essity.com/images-c5/543/661543/original/uk-cutimed-best-practice-statement-antimicrobial-stewardship-wuk.pdf

We remain committed to improving patient outcomes and driving excellence in healthcare delivery. To achieve this, we will expand into additional surgical specialties while continuing to support the development of robust clinical evidence.